Not registered yet? Please contact our project manager Dr. Sara Stöber . This area is only for members of the research consortium.


25 June 2020

Project video & successful 1st patient event at PAE’s annual GA Meeting!

QSPainRelief’s first patient event took place as part of Pain Alliance Europe’s (PAE) annual General Assembly (GA) Meeting this year: Our project’s scientific coordinator, Prof. Dr. Liesbeth de Lange, presented the scope of the project in a 20-min lecture on Wednesday, 24 June 2020. The talk was well-received by the audience of 23 laymen and representatives of European pain patient organisations from 19 different countries. Click below to watch the lecture video on YouTube!

More news


23-24 June 2020

2nd SC Meeting concluded

The 2nd QSPainRelief Steering Committee (SC) Meeting took place on Tuesday & Wednesday, 23-24 June 2020, remotely via GoToMeeting due to the corona crisis. The progress of each work package was presented, upcoming tasks and issues around COVID-19 were discussed, and the data and safety monitoring committee (DSMC) was elected. Despite the unforeseeable challenges, such as closed laboratories and home office, the project is advancing well, especially the in silico modelling.

More events
Personalise and maximize pain relief for individuals suffering from chronic pain

Summary Statement

10 institutions in Europe and the USA collaborate for the next 5 years to help patients suffering from chronic pain. QSPainRelief aims to develop effective drug combination treatments for the improved relief of chronic pain. A quantitative systems pharmacology (QSP) mathematical modelling approach will be used to identify and validate more effective therapeutic interventions by smart combinations of existing drugs. The ultimate goal is to personalise and maximize pain relief for individuals suffering from chronic pain while diminishing side effects.

Learn more


  • Consolidating cutting-edge treatment models for chronic pain
  • Summary Statement
  • Validating novel combinational therapies preclinically in vitro and in vivo
  • Conducting clinical studies to detect functional biomarkers
  • Improving the clinical guidelines for pain relief in stratified patient groups
  • Personalising pain relief treatment for each patient
  • Improving the scientific understanding of chronic pain regarding age, sex, disease and genetic factors


  • Novel concepts of combinational pain relief therapies
  • Improved efficacy and acceptability in the clinic
  • Effective stratification of patients with respect to age, sex, disease and genotype
  • Personalised treatment with unswerving benefits for patients
  • Unique knowledge gain and innovation opportunities